High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience

High-dose capsaicin patch is effective in treatment of neuropathic pain in HIV-associated neuropathy and diabetic neuropathy. There are no studies assessing effectiveness of high-dose capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy. We sought to determine the effectiveness...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Medical oncology (Northwood, London, England) London, England), 2017-09, Vol.34 (9), p.162-162, Article 162
Hauptverfasser: Filipczak-Bryniarska, Iwona, Krzyzewski, Roger M., Kucharz, Jakub, Michalowska-Kaczmarczyk, Anna, Kleja, Justyna, Woron, Jarosław, Strzepek, Katarzyna, Kazior, Lucyna, Wordliczek, Jerzy, Grodzicki, Tomasz, Krzemieniecki, Krzysztof
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 162
container_issue 9
container_start_page 162
container_title Medical oncology (Northwood, London, England)
container_volume 34
creator Filipczak-Bryniarska, Iwona
Krzyzewski, Roger M.
Kucharz, Jakub
Michalowska-Kaczmarczyk, Anna
Kleja, Justyna
Woron, Jarosław
Strzepek, Katarzyna
Kazior, Lucyna
Wordliczek, Jerzy
Grodzicki, Tomasz
Krzemieniecki, Krzysztof
description High-dose capsaicin patch is effective in treatment of neuropathic pain in HIV-associated neuropathy and diabetic neuropathy. There are no studies assessing effectiveness of high-dose capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy. We sought to determine the effectiveness of treatment of pain associated with chemotherapy-induced peripheral neuropathy with high-dose capsaicin patch. Our study group consisted of 18 patients with clinically confirmed oxaliplatin-induced neuropathy. Baseline characteristic including underling disease, received cumulative dose of neurotoxic agent, neuropathic symptoms, prior treatment and initial pain level were recorded. Pain was evaluated with Numeric Rating Scale prior to treatment with high-dose capsaicin and after 1.8 day and after 8 and 12 weeks after introducing treatment. Patients were divided into two groups accordingly to the amount of neurotoxic agent that caused neuropathy (high sensitivity and low sensitivity group). Most frequent symptoms of chemotherapy-induced neuropathy were: pain (88.89%), paresthesis (100%), sock and gloves sensation (100%) and hypoesthesis (100%). Initial pain level was 7.45 ± 1.14. Mean cumulative dose of oxaliplatin after which patients developed symptoms was 648.07 mg/m 2 . Mean pain level after 12 weeks of treatment was 0.20 ± 0.41. When examined according to high and low sensitivity to neurotoxic agent patients with low sensitivity had higher pain reduction, especially after 8 days after introducing treatment (69.55 ± 12.09 vs. 49.40 ± 20.34%; p  = 0.02) and after 12 weeks (96.96 ± 5.56 vs. 83.93 ± 18.59%; p  = 0.04). High-dose capsaicin patch is an effective treatment for pain associated with chemotherapy-induced neuropathy in patients treated with oxaliplatin. Patients with lower sensitivity to neurotoxic agents have better response to treatment and pain reduction.
doi_str_mv 10.1007/s12032-017-1015-1
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5561154</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1930475889</sourcerecordid><originalsourceid>FETCH-LOGICAL-c562t-5a707222c212591c7910d598691ac4460c5bc976c1bab35dbff09394b781e3173</originalsourceid><addsrcrecordid>eNp1kV-L1TAQxYso7h_9AL5IQARfopmkaRofBFlcV1jwRcG3kKbT2yy9STdpxfvtTbnrsgo-Zcj8zpkZTlW9APYWGFPvMnAmOGWgKDCQFB5VpyClpiDgx-NSC6kokw07qc5yvmGMg-T6aXXC2xa0Eu1pdXvldyPtY0bSvibOztl65wOZ7eJGUooloV32GBYSB-JG3MdlxGTnA_WhXx32ZMbk5-1vIgHXFIt0PLwn2YfdhNQVKSaCvzYMg8Nn1ZPBThmf373n1ffLT98uruj1189fLj5eUycbvlBpFVOcc8eBSw1OaWC91G2jwbq6bpiTndOqcdDZTsi-Gwamha471QIKUOK8-nD0ndduj_22R1nRzMnvbTqYaL35uxP8aHbxp5GyAZB1MXhzZ5Di7Yp5MXufHU6TDRjXbEALVivZtrqgr_5Bb-KaQjmvUFyLthGMFQqOlEsx54TD_TLAzBaoOQZqSqBmC9RA0bx8eMW94k-CBeBHIJdW2GF6MPq_rr8B82mshw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1929386300</pqid></control><display><type>article</type><title>High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Filipczak-Bryniarska, Iwona ; Krzyzewski, Roger M. ; Kucharz, Jakub ; Michalowska-Kaczmarczyk, Anna ; Kleja, Justyna ; Woron, Jarosław ; Strzepek, Katarzyna ; Kazior, Lucyna ; Wordliczek, Jerzy ; Grodzicki, Tomasz ; Krzemieniecki, Krzysztof</creator><creatorcontrib>Filipczak-Bryniarska, Iwona ; Krzyzewski, Roger M. ; Kucharz, Jakub ; Michalowska-Kaczmarczyk, Anna ; Kleja, Justyna ; Woron, Jarosław ; Strzepek, Katarzyna ; Kazior, Lucyna ; Wordliczek, Jerzy ; Grodzicki, Tomasz ; Krzemieniecki, Krzysztof</creatorcontrib><description>High-dose capsaicin patch is effective in treatment of neuropathic pain in HIV-associated neuropathy and diabetic neuropathy. There are no studies assessing effectiveness of high-dose capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy. We sought to determine the effectiveness of treatment of pain associated with chemotherapy-induced peripheral neuropathy with high-dose capsaicin patch. Our study group consisted of 18 patients with clinically confirmed oxaliplatin-induced neuropathy. Baseline characteristic including underling disease, received cumulative dose of neurotoxic agent, neuropathic symptoms, prior treatment and initial pain level were recorded. Pain was evaluated with Numeric Rating Scale prior to treatment with high-dose capsaicin and after 1.8 day and after 8 and 12 weeks after introducing treatment. Patients were divided into two groups accordingly to the amount of neurotoxic agent that caused neuropathy (high sensitivity and low sensitivity group). Most frequent symptoms of chemotherapy-induced neuropathy were: pain (88.89%), paresthesis (100%), sock and gloves sensation (100%) and hypoesthesis (100%). Initial pain level was 7.45 ± 1.14. Mean cumulative dose of oxaliplatin after which patients developed symptoms was 648.07 mg/m 2 . Mean pain level after 12 weeks of treatment was 0.20 ± 0.41. When examined according to high and low sensitivity to neurotoxic agent patients with low sensitivity had higher pain reduction, especially after 8 days after introducing treatment (69.55 ± 12.09 vs. 49.40 ± 20.34%; p  = 0.02) and after 12 weeks (96.96 ± 5.56 vs. 83.93 ± 18.59%; p  = 0.04). High-dose capsaicin patch is an effective treatment for pain associated with chemotherapy-induced neuropathy in patients treated with oxaliplatin. Patients with lower sensitivity to neurotoxic agents have better response to treatment and pain reduction.</description><identifier>ISSN: 1357-0560</identifier><identifier>EISSN: 1559-131X</identifier><identifier>DOI: 10.1007/s12032-017-1015-1</identifier><identifier>PMID: 28819738</identifier><language>eng</language><publisher>New York: Springer US</publisher><subject>Aged ; Analgesics, Non-Narcotic - administration &amp; dosage ; Analgesics, Non-Narcotic - therapeutic use ; Antineoplastic Agents - adverse effects ; Capsaicin - administration &amp; dosage ; Capsaicin - therapeutic use ; Chemotherapy ; Diabetic neuropathy ; Dose-Response Relationship, Drug ; Female ; Hematology ; Humans ; Internal Medicine ; Male ; Medicine ; Medicine &amp; Public Health ; Middle Aged ; Neuralgia - chemically induced ; Neuralgia - drug therapy ; Neurotoxicity ; Oncology ; Organoplatinum Compounds - adverse effects ; Original Paper ; Pain ; Pathology ; Peripheral neuropathy ; Transdermal Patch ; Treatment Outcome</subject><ispartof>Medical oncology (Northwood, London, England), 2017-09, Vol.34 (9), p.162-162, Article 162</ispartof><rights>The Author(s) 2017</rights><rights>Medical Oncology is a copyright of Springer, 2017.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c562t-5a707222c212591c7910d598691ac4460c5bc976c1bab35dbff09394b781e3173</citedby><cites>FETCH-LOGICAL-c562t-5a707222c212591c7910d598691ac4460c5bc976c1bab35dbff09394b781e3173</cites><orcidid>0000-0001-5388-8910</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12032-017-1015-1$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12032-017-1015-1$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,777,781,882,27905,27906,41469,42538,51300</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28819738$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Filipczak-Bryniarska, Iwona</creatorcontrib><creatorcontrib>Krzyzewski, Roger M.</creatorcontrib><creatorcontrib>Kucharz, Jakub</creatorcontrib><creatorcontrib>Michalowska-Kaczmarczyk, Anna</creatorcontrib><creatorcontrib>Kleja, Justyna</creatorcontrib><creatorcontrib>Woron, Jarosław</creatorcontrib><creatorcontrib>Strzepek, Katarzyna</creatorcontrib><creatorcontrib>Kazior, Lucyna</creatorcontrib><creatorcontrib>Wordliczek, Jerzy</creatorcontrib><creatorcontrib>Grodzicki, Tomasz</creatorcontrib><creatorcontrib>Krzemieniecki, Krzysztof</creatorcontrib><title>High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience</title><title>Medical oncology (Northwood, London, England)</title><addtitle>Med Oncol</addtitle><addtitle>Med Oncol</addtitle><description>High-dose capsaicin patch is effective in treatment of neuropathic pain in HIV-associated neuropathy and diabetic neuropathy. There are no studies assessing effectiveness of high-dose capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy. We sought to determine the effectiveness of treatment of pain associated with chemotherapy-induced peripheral neuropathy with high-dose capsaicin patch. Our study group consisted of 18 patients with clinically confirmed oxaliplatin-induced neuropathy. Baseline characteristic including underling disease, received cumulative dose of neurotoxic agent, neuropathic symptoms, prior treatment and initial pain level were recorded. Pain was evaluated with Numeric Rating Scale prior to treatment with high-dose capsaicin and after 1.8 day and after 8 and 12 weeks after introducing treatment. Patients were divided into two groups accordingly to the amount of neurotoxic agent that caused neuropathy (high sensitivity and low sensitivity group). Most frequent symptoms of chemotherapy-induced neuropathy were: pain (88.89%), paresthesis (100%), sock and gloves sensation (100%) and hypoesthesis (100%). Initial pain level was 7.45 ± 1.14. Mean cumulative dose of oxaliplatin after which patients developed symptoms was 648.07 mg/m 2 . Mean pain level after 12 weeks of treatment was 0.20 ± 0.41. When examined according to high and low sensitivity to neurotoxic agent patients with low sensitivity had higher pain reduction, especially after 8 days after introducing treatment (69.55 ± 12.09 vs. 49.40 ± 20.34%; p  = 0.02) and after 12 weeks (96.96 ± 5.56 vs. 83.93 ± 18.59%; p  = 0.04). High-dose capsaicin patch is an effective treatment for pain associated with chemotherapy-induced neuropathy in patients treated with oxaliplatin. Patients with lower sensitivity to neurotoxic agents have better response to treatment and pain reduction.</description><subject>Aged</subject><subject>Analgesics, Non-Narcotic - administration &amp; dosage</subject><subject>Analgesics, Non-Narcotic - therapeutic use</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Capsaicin - administration &amp; dosage</subject><subject>Capsaicin - therapeutic use</subject><subject>Chemotherapy</subject><subject>Diabetic neuropathy</subject><subject>Dose-Response Relationship, Drug</subject><subject>Female</subject><subject>Hematology</subject><subject>Humans</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine &amp; Public Health</subject><subject>Middle Aged</subject><subject>Neuralgia - chemically induced</subject><subject>Neuralgia - drug therapy</subject><subject>Neurotoxicity</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Original Paper</subject><subject>Pain</subject><subject>Pathology</subject><subject>Peripheral neuropathy</subject><subject>Transdermal Patch</subject><subject>Treatment Outcome</subject><issn>1357-0560</issn><issn>1559-131X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kV-L1TAQxYso7h_9AL5IQARfopmkaRofBFlcV1jwRcG3kKbT2yy9STdpxfvtTbnrsgo-Zcj8zpkZTlW9APYWGFPvMnAmOGWgKDCQFB5VpyClpiDgx-NSC6kokw07qc5yvmGMg-T6aXXC2xa0Eu1pdXvldyPtY0bSvibOztl65wOZ7eJGUooloV32GBYSB-JG3MdlxGTnA_WhXx32ZMbk5-1vIgHXFIt0PLwn2YfdhNQVKSaCvzYMg8Nn1ZPBThmf373n1ffLT98uruj1189fLj5eUycbvlBpFVOcc8eBSw1OaWC91G2jwbq6bpiTndOqcdDZTsi-Gwamha471QIKUOK8-nD0ndduj_22R1nRzMnvbTqYaL35uxP8aHbxp5GyAZB1MXhzZ5Di7Yp5MXufHU6TDRjXbEALVivZtrqgr_5Bb-KaQjmvUFyLthGMFQqOlEsx54TD_TLAzBaoOQZqSqBmC9RA0bx8eMW94k-CBeBHIJdW2GF6MPq_rr8B82mshw</recordid><startdate>20170901</startdate><enddate>20170901</enddate><creator>Filipczak-Bryniarska, Iwona</creator><creator>Krzyzewski, Roger M.</creator><creator>Kucharz, Jakub</creator><creator>Michalowska-Kaczmarczyk, Anna</creator><creator>Kleja, Justyna</creator><creator>Woron, Jarosław</creator><creator>Strzepek, Katarzyna</creator><creator>Kazior, Lucyna</creator><creator>Wordliczek, Jerzy</creator><creator>Grodzicki, Tomasz</creator><creator>Krzemieniecki, Krzysztof</creator><general>Springer US</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-5388-8910</orcidid></search><sort><creationdate>20170901</creationdate><title>High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience</title><author>Filipczak-Bryniarska, Iwona ; Krzyzewski, Roger M. ; Kucharz, Jakub ; Michalowska-Kaczmarczyk, Anna ; Kleja, Justyna ; Woron, Jarosław ; Strzepek, Katarzyna ; Kazior, Lucyna ; Wordliczek, Jerzy ; Grodzicki, Tomasz ; Krzemieniecki, Krzysztof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c562t-5a707222c212591c7910d598691ac4460c5bc976c1bab35dbff09394b781e3173</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Aged</topic><topic>Analgesics, Non-Narcotic - administration &amp; dosage</topic><topic>Analgesics, Non-Narcotic - therapeutic use</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Capsaicin - administration &amp; dosage</topic><topic>Capsaicin - therapeutic use</topic><topic>Chemotherapy</topic><topic>Diabetic neuropathy</topic><topic>Dose-Response Relationship, Drug</topic><topic>Female</topic><topic>Hematology</topic><topic>Humans</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine &amp; Public Health</topic><topic>Middle Aged</topic><topic>Neuralgia - chemically induced</topic><topic>Neuralgia - drug therapy</topic><topic>Neurotoxicity</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Original Paper</topic><topic>Pain</topic><topic>Pathology</topic><topic>Peripheral neuropathy</topic><topic>Transdermal Patch</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Filipczak-Bryniarska, Iwona</creatorcontrib><creatorcontrib>Krzyzewski, Roger M.</creatorcontrib><creatorcontrib>Kucharz, Jakub</creatorcontrib><creatorcontrib>Michalowska-Kaczmarczyk, Anna</creatorcontrib><creatorcontrib>Kleja, Justyna</creatorcontrib><creatorcontrib>Woron, Jarosław</creatorcontrib><creatorcontrib>Strzepek, Katarzyna</creatorcontrib><creatorcontrib>Kazior, Lucyna</creatorcontrib><creatorcontrib>Wordliczek, Jerzy</creatorcontrib><creatorcontrib>Grodzicki, Tomasz</creatorcontrib><creatorcontrib>Krzemieniecki, Krzysztof</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medical oncology (Northwood, London, England)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Filipczak-Bryniarska, Iwona</au><au>Krzyzewski, Roger M.</au><au>Kucharz, Jakub</au><au>Michalowska-Kaczmarczyk, Anna</au><au>Kleja, Justyna</au><au>Woron, Jarosław</au><au>Strzepek, Katarzyna</au><au>Kazior, Lucyna</au><au>Wordliczek, Jerzy</au><au>Grodzicki, Tomasz</au><au>Krzemieniecki, Krzysztof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience</atitle><jtitle>Medical oncology (Northwood, London, England)</jtitle><stitle>Med Oncol</stitle><addtitle>Med Oncol</addtitle><date>2017-09-01</date><risdate>2017</risdate><volume>34</volume><issue>9</issue><spage>162</spage><epage>162</epage><pages>162-162</pages><artnum>162</artnum><issn>1357-0560</issn><eissn>1559-131X</eissn><abstract>High-dose capsaicin patch is effective in treatment of neuropathic pain in HIV-associated neuropathy and diabetic neuropathy. There are no studies assessing effectiveness of high-dose capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy. We sought to determine the effectiveness of treatment of pain associated with chemotherapy-induced peripheral neuropathy with high-dose capsaicin patch. Our study group consisted of 18 patients with clinically confirmed oxaliplatin-induced neuropathy. Baseline characteristic including underling disease, received cumulative dose of neurotoxic agent, neuropathic symptoms, prior treatment and initial pain level were recorded. Pain was evaluated with Numeric Rating Scale prior to treatment with high-dose capsaicin and after 1.8 day and after 8 and 12 weeks after introducing treatment. Patients were divided into two groups accordingly to the amount of neurotoxic agent that caused neuropathy (high sensitivity and low sensitivity group). Most frequent symptoms of chemotherapy-induced neuropathy were: pain (88.89%), paresthesis (100%), sock and gloves sensation (100%) and hypoesthesis (100%). Initial pain level was 7.45 ± 1.14. Mean cumulative dose of oxaliplatin after which patients developed symptoms was 648.07 mg/m 2 . Mean pain level after 12 weeks of treatment was 0.20 ± 0.41. When examined according to high and low sensitivity to neurotoxic agent patients with low sensitivity had higher pain reduction, especially after 8 days after introducing treatment (69.55 ± 12.09 vs. 49.40 ± 20.34%; p  = 0.02) and after 12 weeks (96.96 ± 5.56 vs. 83.93 ± 18.59%; p  = 0.04). High-dose capsaicin patch is an effective treatment for pain associated with chemotherapy-induced neuropathy in patients treated with oxaliplatin. Patients with lower sensitivity to neurotoxic agents have better response to treatment and pain reduction.</abstract><cop>New York</cop><pub>Springer US</pub><pmid>28819738</pmid><doi>10.1007/s12032-017-1015-1</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-5388-8910</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1357-0560
ispartof Medical oncology (Northwood, London, England), 2017-09, Vol.34 (9), p.162-162, Article 162
issn 1357-0560
1559-131X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_5561154
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Aged
Analgesics, Non-Narcotic - administration & dosage
Analgesics, Non-Narcotic - therapeutic use
Antineoplastic Agents - adverse effects
Capsaicin - administration & dosage
Capsaicin - therapeutic use
Chemotherapy
Diabetic neuropathy
Dose-Response Relationship, Drug
Female
Hematology
Humans
Internal Medicine
Male
Medicine
Medicine & Public Health
Middle Aged
Neuralgia - chemically induced
Neuralgia - drug therapy
Neurotoxicity
Oncology
Organoplatinum Compounds - adverse effects
Original Paper
Pain
Pathology
Peripheral neuropathy
Transdermal Patch
Treatment Outcome
title High-dose 8% capsaicin patch in treatment of chemotherapy-induced peripheral neuropathy: single-center experience
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T02%3A54%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High-dose%208%25%20capsaicin%20patch%20in%20treatment%20of%20chemotherapy-induced%20peripheral%20neuropathy:%20single-center%20experience&rft.jtitle=Medical%20oncology%20(Northwood,%20London,%20England)&rft.au=Filipczak-Bryniarska,%20Iwona&rft.date=2017-09-01&rft.volume=34&rft.issue=9&rft.spage=162&rft.epage=162&rft.pages=162-162&rft.artnum=162&rft.issn=1357-0560&rft.eissn=1559-131X&rft_id=info:doi/10.1007/s12032-017-1015-1&rft_dat=%3Cproquest_pubme%3E1930475889%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1929386300&rft_id=info:pmid/28819738&rfr_iscdi=true